April 5, 2024 - Following consultations with stakeholders in the late summer and early fall of 2023, we have finalized the principles and conditions for the new pCPA Temporary Access Process (pTAP).
We are now ready to accept drugs through pTAP, which has been designed to allow patients temporary access to drugs with promising early results, while clinical evidence continues to be collected and reviewed.
We want to thank the pharmaceutical industry, patient groups and clinicians who participated in the consultation and provided valuable feedback.
More information is available on our pTAP webpage, including an outline of the steps in the process and an FAQ.